PP and PIM prevalence
The median concomitant medications were 4 (range = 0–16; interquartile
range [IQR] = 1–6) at EGFR-TKI treatment initiation. The PP
prevalence (≥5 concomitant medications) was 89/232 (38.4%)
(Figure 2 ). According to STOPP ver. 2 criteria, 74 (31.9%)
older advanced NSCLC patients took at least one medication that was
deemed PIM. Of these 74 PIM-STOPP
v2(+) patients, 16 (21.6%) violated three or more STOPP ver. 2 criteria
checkpoints (Supplementary Table 1 ). According to our criteria,
defined in the Materials and Methods section, 66 (28.5%) patients took
at least one medication deemed PIM-TKI (Supplementary Table 2 ).
PP(+) patients were more likely to take at least one PIM-STOPP v2
(51.7% vs. 19.6%; P < 0.001; odds ratio [OR] =
4.36; 95% confidence interval [CI] = 2.35–8.25) and PIM-TKI
(52.3% vs. 14.2%; P < 0.001; OR = 6.56; 95% CI =
3.38–13.15) compared to PP(−) patients.